• Explore /
  • Poster
  • / A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Abstract Video & Slides Poster

Authors

null

Manish R. Patel

Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL

Manish R. Patel , Todd Michael Bauer , Antonio Jimeno , Ding Wang , Patricia LoRusso , Khanh Tu Do , Salomon M. Stemmer , Corinne Maurice-Dror , Ravit Geva , Sima Zacharek , Andressa S Laino , Jing Sun , Joshua Frederick , Honghong Zhou , William Randolph , Pamela Sarah Cohen , Robert S. Meehan , Ryan J. Sullivan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT03739931

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3092)

DOI

10.1200/JCO.2020.38.15_suppl.3092

Abstract #

3092

Poster Bd #

156

Abstract Disclosures

Similar Posters

First Author: Raffit Hassan

First Author: Michele Petruzzelli

First Author: Iwona A. Lugowska

First Author: Susanna Varkey Ulahannan